VascVersa join the NA-ATCC

VascVersa were delighted to become an NA-ATCC partner. The consortium consists of twenty industry, NHS and academic organisations lead by Newcastle hospitals and the SNBTS with a remit to develop systems and infrastructure to support the delivery of Cell and Gene therapies.

VascVersa were also awarded funding through this consortium for a 3-month project to establish a potency assay for Angicyte therapy.